Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen

Sana Biotechnology (NASDAQ:SANA) was upgraded by stock analysts at TD Cowen from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday,Benzinga reports.

Several other equities analysts have also weighed in on SANA. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Sana Biotechnology in a report on Wednesday, November 27th. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $1.65 on Wednesday. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $12.00. The firm’s 50-day moving average is $2.38 and its two-hundred day moving average is $4.07. The stock has a market capitalization of $368.39 million, a P/E ratio of -1.18 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. As a group, analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several large investors have recently made changes to their positions in SANA. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology during the 3rd quarter worth about $29,000. Stifel Financial Corp acquired a new position in Sana Biotechnology in the third quarter worth approximately $43,000. EP Wealth Advisors LLC bought a new position in shares of Sana Biotechnology during the 3rd quarter valued at $45,000. Blue Trust Inc. lifted its position in shares of Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after buying an additional 12,154 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in Sana Biotechnology in the 2nd quarter worth approximately $73,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.